ADB-106

About Adolore BioTherapeutics

Adolore BioTherapeutics is developing a novel neuromodulation platform centered on a proprietary gene therapy that delivers a novel CA8 therapeutic peptide directly inside targeted neurons and nerve fibers. Their lead programs target chronic osteoarthritis knee pain and the rare condition erythromelalgia, with a broader pipeline extending into epilepsy, hearing loss, and ophthalmology. The company's mission is to create safe, effective, and accessible non-opioid therapies to combat the opioid crisis by providing highly localized, disease-modifying treatments.

Therapeutic Areas

Other Ophthalmology Drugs